---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-039945"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T08:34:39.171127+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences Q3 revenue $9.1M (+11% YoY); expects FY2023 revenue >$40M

## Summary
- Q3 net revenue $9.1M, up 11% from $8.2M; test volume up 11% YoY.
- Loss from continuing ops $(0.5)M vs $(1.3)M; adjusted EBITDA $0.4M vs $0.1M.
- Repaid $2.5M Comerica line of credit and $3M Terminal Payment to BroadOak; renegotiated long-term debt.
- Cash balance $5.0M at Sept 30, 2023; cash collections $9.8M vs $7.6M.
- Expects full-year 2023 revenue to exceed $40M.

## SEC filing metadata
- accession: 0001493152-23-039945
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315223039945/0001493152-23-039945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315223039945/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-039945
- JSON: https://secwatch.observer/filing/0001493152-23-039945.json
- Plain text: https://secwatch.observer/filing/0001493152-23-039945.txt

## Key facts
- Earnings Releases
  INTERPACE BIOSCIENCES, INC. reported nine months ended September 30, 2023 results: revenue $29.9 million. Guidance reaffirmed.
  - Period: nine months ended September 30, 2023
  - Revenue: $29.9 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: For the Nine Months Ended September 30, 2023 as Compared to the Nine Months Ended September 30, 2022 ● Net Revenue was $29.9 million, an increase of 27% from $23.5 million for the prior year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1054102/000149315223039945/0001493152-23-039945-index.htm
- Earnings Releases
  INTERPACE BIOSCIENCES, INC. reported third quarter ended September 30, 2023 results: revenue $9.1 million. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2023
  - Revenue: $9.1 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: in such filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results ● Q3 Revenue of $9.1 million; an 11% increase year-over-year ● Q3 Test volume up 11% year-over-year ● Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1054102/000149315223039945/0001493152-23-039945-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.